Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 8,625 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson Disease
Interventions
Placebo, UCB0022
Other · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
35 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
61
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 53 more
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
Conditions
Weight Loss
Interventions
VK2735, Placebo
Biological
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
54
States / cities
Fairhope, Alabama • Mobile, Alabama • Beverly Hills, California + 47 more
Not listed Not applicable Interventional Accepts healthy volunteers

Feasibility and Acceptability of Music Therapy for Chronic Pain

NCT05426941
Conditions
Chronic Pain
Interventions
Music Imagery, Music Listening
Behavioral
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Urothelial Carcinoma
Interventions
Carboplatin, Gemcitabine, Atezolizumab, Docetaxel
Drug
Lead sponsor
Nabil Adra
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Indianapolis, Indiana • Omaha, Nebraska • Albuquerque, New Mexico + 1 more
Conditions
Type 2 Diabetes
Interventions
Colesevelam hydrochloride
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
62
States / cities
Birmingham, Alabama • Tuscumbia, Alabama • Jonesboro, Arkansas + 59 more
Conditions
Dyslipidemia
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
14
States / cities
Huntsville, Alabama • Lincoln, California • Palm Springs, California + 11 more
Conditions
Thymoma and Thymic Carcinoma
Interventions
octreotide acetate, prednisone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
24
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 18 more
Conditions
Glaucoma and Ocular Hypertension
Interventions
ENV515-3 Travoprost XR, ENV515-1 Travoprost XR, ENV515-3-2 Travoprost XR
Drug
Lead sponsor
Envisia Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Garden Grove, California • Inglewood, California + 11 more
Conditions
Chronic Hand Eczema
Interventions
ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Beverly Hills, California • Encino, California • Fremont, California + 21 more
Conditions
Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive
Interventions
Bezuclastinib
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Normal, Illinois + 17 more
Conditions
Pancreatic Cancer
Interventions
dehydrated alcohol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Alzheimer's Disease, Dementia
Interventions
care management
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Diabetes Mellitus, Type 2
Interventions
UBT251, UBT251 Placebo, Semaglutide, Semaglutide Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
25
States / cities
Birmingham, Alabama • Fountain Valley, California • Long Beach, California + 21 more
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Farletuzumab, Chemo Plus Far
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
18
States / cities
San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more
Conditions
Neoplasms, Hematologic
Interventions
120 mg LY2784544
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
23
States / cities
Rogers, Arkansas • Burbank, California • Norwalk, Connecticut + 19 more
Conditions
Brain Tumors, Central Nervous System Tumors
Interventions
DNA ploidy analysis, comparative genomic hybridization, cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
56
States / cities
Phoenix, Arizona • Downey, California • Loma Linda, California + 48 more
Conditions
Airway Morbidity
Interventions
LMA, ETT
Device
Lead sponsor
Indiana University
Other
Eligibility
3 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
23
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 17 more
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Orange, California • San Francisco, California • Miami, Florida + 9 more
Conditions
Neoplasm Metastasis
Interventions
PF-07265807, Sasanlimab, Axitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Conditions
Malignant Glioma
Interventions
Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
111
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more